Delayed toxicities following CAR T cell therapy for multiple myeloma may be linked and could potentially be prevented, according to new findings. The study explores the relationship between late-onset side effects experienced by patients after undergoing this advanced treatment.
CAR T cell therapy is a form of immunotherapy used in treating multiple myeloma, a type of blood cancer. While the therapy has shown promise in managing the disease, some patients develop toxicities weeks or months after treatment. Researchers are investigating whether these delayed complications share common mechanisms and if interventions can reduce their occurrence.
The research highlights the importance of monitoring patients long-term after CAR T cell therapy and suggests that early identification of risk factors could help prevent or lessen these toxicities.
